Pennsylvania-based Janssen Biotech is presenting 15 abstracts at the 2016 Digestive Disease Week (DDW) annual meeting May 21-24 in San Diego, California. Presentations will include data from the Janssen gastroenterology portfolio of injection and infusion biologic therapies, primarily results from the pivotal Phase 3 (IM-UNITI) Stelara (ustekinumab) maintenance therapy study for adults with moderate to severe Crohn’s disease; results of an open-label investigation on safety and efficacy outcomes for Simponi (golimumab) in pediatric patients with ulcerative colitis (UC); and safety data from a cohort of elderly Crohn’s disease patients from the Remicade TREAT registry. "At Janssen, we are proud of our leadership position in gastroenterology and are pleased to be presenting our breadth of new data at DDW," said Andrew Greenspan, MD, Janssen vice president of scientific affairs, in a press release. "After more than 20 years focused on inflammatory bowel disease, we understand that significant unmet medical need still exists and are hopeful that our research can potentially lead to novel therapeutics that can change lives for the better." Stelara (ustekinumab) is a human interleukin (IL)-12 and IL-23 antagonist, approved in the United States for the treatment of adults with moderate to severe plaque psoriasis who are eligible to receive phototherapy or systemic therapy, and for adults with active psoriatic arthritis alone or in combination with methotrexate (MTX). The drug is being tested as a therapy for Crohn's disease.